Dendritic-cell-based therapeutic cancer vaccines.

Document Type

Article

Publication Date

7-25-2013

Keywords

Cancer Vaccines, Dendritic Cells, Humans, Immunotherapy, Adoptive, Models, Immunological, Neoplasms, T-Lymphocytes

JAX Source

Immunity 2013 Jul 25; 39(1):38-48

Volume

39

Issue

1

First Page

38

Last Page

48

ISSN

1097-4180

PMID

23890062

Abstract

The past decade has seen tremendous developments in novel cancer therapies through the targeting of tumor-cell-intrinsic pathways whose activity is linked to genetic alterations and the targeting of tumor-cell-extrinsic factors, such as growth factors. Furthermore, immunotherapies are entering the clinic at an unprecedented speed after the demonstration that T cells can efficiently reject tumors and that their antitumor activity can be enhanced with antibodies against immune-regulatory molecules (checkpoint blockade). Current immunotherapy strategies include monoclonal antibodies against tumor cells or immune-regulatory molecules, cell-based therapies such as adoptive transfer of ex-vivo-activated T cells and natural killer cells, and cancer vaccines. Herein, we discuss the immunological basis for therapeutic cancer vaccines and how the current understanding of dendritic cell and T cell biology might enable the development of next-generation curative therapies for individuals with cancer. Immunity 2013 Jul 25; 39(1):38-48

Link to Full Text

Share

COinS